Skip to main content
Top
Published in: Medical Oncology 1/2013

01-03-2013 | Original Paper

Expression of NCAM (CD56), chromogranin A, synaptophysin, c-KIT (CD117) and PDGFRA in normal non-neoplastic skin and basal cell carcinoma: an immunohistochemical study of 66 consecutive cases

Author: Tadashi Terada

Published in: Medical Oncology | Issue 1/2013

Login to get access

Abstract

The expression of NCAM (CD56), chromogranin A, synaptophysin, c-KIT (CD117) and PDGFRA in normal non-neoplastic skin and basal cell carcinoma (BCC) has rarely been investigated. The author immunohistochemically examined the expression of these molecules in 66 consecutive cases of BCC. In non-tumorous skin, NCAM chromogranin A, synaptophysin, c-KIT and PDGFRA expression was seen in the basal cell of the epidermis. NCAM, c-KIT and PDGFRA expression was also seen in the sweat glands and outer cells of hair follicles, but chromogranin and synaptophysin expression was not identified in these structures. In BCC, NCAM expression was seen in 95 % (63/66 cases). Its expression was membranous. Chromogranin A expression was recognized in 27 % (18/66 cases). Its expression was cytoplasmic. Synaptophysin expression was seen in 18 % (12/66 cases). Its expression was membranous and cytoplasmic. c-KIT expression was noted in 93 % (61/66 cases). Its expression was membranous and focally cytoplasmic. PDGFRA expression was seen in 65 % (43/66 cases). Its expression was membranous and cytoplasmic. The expression of these molecules in normal non-tumorous skin is a new finding. The expression of c-KIT and PDGFRA in BCC is also a new finding. In conclusion, the author described the normal (non-neoplastic) distribution of NCAM, chromogranin A, synaptophysin, c-KIT and PDGFRA. In addition, the author showed that, in cutaneous BCC, the expression of NCAM and c-KIT was high (95 and 93 % respectively), PDGFRA was intermediate (65 %), and chromogranin A and synaptophysin was relatively low (27 and 18 %, respectively).
Literature
1.
go back to reference Kossard S, Epstein Jr EH, Cerio R, Yu LL, Weedon D. Basal cell carcinoma. In: LeBoit PE, Burg G, Weedon D, Sarasin A, editors. World health organization classification of tumours. Pathology and genetics of skin tumours. Lyon: IARC Press; 2006. p. 13–19. Kossard S, Epstein Jr EH, Cerio R, Yu LL, Weedon D. Basal cell carcinoma. In: LeBoit PE, Burg G, Weedon D, Sarasin A, editors. World health organization classification of tumours. Pathology and genetics of skin tumours. Lyon: IARC Press; 2006. p. 13–19.
2.
go back to reference Dardi LE, Memoli VA, Gould VE. Neuroendocrine differentiation in basal cell carcinoma. J Cutan Pathol. 1981;8:335–41.PubMedCrossRef Dardi LE, Memoli VA, Gould VE. Neuroendocrine differentiation in basal cell carcinoma. J Cutan Pathol. 1981;8:335–41.PubMedCrossRef
3.
go back to reference Visser R, Bosman FT. Neuroendocrine differentiation in basal cell carcinoma: a retrospective immunohistochemical and ultrastructural study. J Cutan Pathol. 1985;12:117–24.PubMedCrossRef Visser R, Bosman FT. Neuroendocrine differentiation in basal cell carcinoma: a retrospective immunohistochemical and ultrastructural study. J Cutan Pathol. 1985;12:117–24.PubMedCrossRef
4.
go back to reference George E, Swanson PE, Wick MR. Neuroendocrine differentiation in basal cell carcinoma: an immunohistochemical study. Am J Dermatopathol. 1989;11:131–5.PubMedCrossRef George E, Swanson PE, Wick MR. Neuroendocrine differentiation in basal cell carcinoma: an immunohistochemical study. Am J Dermatopathol. 1989;11:131–5.PubMedCrossRef
5.
go back to reference Ishida M, Kurashima R, Okabe H. Aberrant expression of class III beta-tubulin in basal cell carcinoma of the skin. Oncol Rep. 2009;22:733–7.PubMed Ishida M, Kurashima R, Okabe H. Aberrant expression of class III beta-tubulin in basal cell carcinoma of the skin. Oncol Rep. 2009;22:733–7.PubMed
6.
go back to reference Miettinen M, Lasota J. KIT (CD117): a review on expression in normal and neoplastic tissue, and mutations and their clinicopathologic correlation. Appl Immunohistochem Mol Morphol. 2005;13:205–20.PubMedCrossRef Miettinen M, Lasota J. KIT (CD117): a review on expression in normal and neoplastic tissue, and mutations and their clinicopathologic correlation. Appl Immunohistochem Mol Morphol. 2005;13:205–20.PubMedCrossRef
7.
go back to reference Terada T, Kawaguchi M, Furukawa K, Sekido Y, Osamura Y. Minute mixed ductal-endocrine carcinoma of the pancreas with predominant intraductal growth. Pathol Int. 2002;52:740–6.PubMedCrossRef Terada T, Kawaguchi M, Furukawa K, Sekido Y, Osamura Y. Minute mixed ductal-endocrine carcinoma of the pancreas with predominant intraductal growth. Pathol Int. 2002;52:740–6.PubMedCrossRef
8.
go back to reference Terada T, Kawaguchi M. Primary clear cell adenocarcinoma of the peritoneum. Tohoku J Exp Med. 2005;206:271–5.PubMedCrossRef Terada T, Kawaguchi M. Primary clear cell adenocarcinoma of the peritoneum. Tohoku J Exp Med. 2005;206:271–5.PubMedCrossRef
9.
go back to reference Beljaards RC, Kirtschig G, Boorsma DM. Expression of neural cell adhesion molecule (CD56) in basal and squamous cell carcinoma. Dermatol Surg. 2008;34:1577–79. Beljaards RC, Kirtschig G, Boorsma DM. Expression of neural cell adhesion molecule (CD56) in basal and squamous cell carcinoma. Dermatol Surg. 2008;34:1577–79.
10.
go back to reference Tsuura Y, Hiraki H, Watanabe K, Igarashi S, Shimamura K, Fukuda T, Suzuki T, Seito T. Preferential localization of c-kit product in tissue mast cells, basal cells of skin, epithelial cells of breast, small cell lung carcinoma and seminoma/dysgerminoma in human: immunohistochemical study on formalin-fixed and paraffin-embedded tissues. Virchows Arch. 1994;424:135–41.PubMedCrossRef Tsuura Y, Hiraki H, Watanabe K, Igarashi S, Shimamura K, Fukuda T, Suzuki T, Seito T. Preferential localization of c-kit product in tissue mast cells, basal cells of skin, epithelial cells of breast, small cell lung carcinoma and seminoma/dysgerminoma in human: immunohistochemical study on formalin-fixed and paraffin-embedded tissues. Virchows Arch. 1994;424:135–41.PubMedCrossRef
11.
go back to reference Blumming P, Nilsson O, Ahlman H, Welbencer A, Andersson MK, Sjolund K, Nilsson B. Gastrointestinal strumal tumor regularly express synaptic vesicle proteins: evidence of a neuroendocrine phenotype. Endocr Relat Cancer. 2007;14:853–63.CrossRef Blumming P, Nilsson O, Ahlman H, Welbencer A, Andersson MK, Sjolund K, Nilsson B. Gastrointestinal strumal tumor regularly express synaptic vesicle proteins: evidence of a neuroendocrine phenotype. Endocr Relat Cancer. 2007;14:853–63.CrossRef
12.
go back to reference Xie J, Aszterbaum M, Zhang X, Bonifas JM, Zachary C, Epstein E, McCormick F. A role of PGDFRα in basal cell carcinoma proliferation. Proc Natl Acad Sci USA. 2001;98:9255–9.PubMedCrossRef Xie J, Aszterbaum M, Zhang X, Bonifas JM, Zachary C, Epstein E, McCormick F. A role of PGDFRα in basal cell carcinoma proliferation. Proc Natl Acad Sci USA. 2001;98:9255–9.PubMedCrossRef
Metadata
Title
Expression of NCAM (CD56), chromogranin A, synaptophysin, c-KIT (CD117) and PDGFRA in normal non-neoplastic skin and basal cell carcinoma: an immunohistochemical study of 66 consecutive cases
Author
Tadashi Terada
Publication date
01-03-2013
Publisher
Springer US
Published in
Medical Oncology / Issue 1/2013
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-012-0444-0

Other articles of this Issue 1/2013

Medical Oncology 1/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.